SLC5A2 and diabetic ketoacidosis: Despite these benefits, SGLT-2 inhibitors have been associated with numerous adverse events such as genitourinary tract infections, volume depletion, and diabetic ketoacidosis (DKA), in particular euglycemic ketoacidosis, due in part to their mechanism of action [5].